Helmut Brunar

Dr. Helmut Brunar is a highly committed executive with far-reaching expertise in pharma and biotech. Before joining as Viravaxx’ CEO, he managed commercial supply chains at Johnson & Johnson’s COVID-19 vaccine program. From 2009 to 2020, he was CEO & Chairman of the Board at Axentis Pharma AG of Switzerland, a drug development company advancing AX-TOBRA as candidate therapy for cystic fibrosis.